369 related articles for article (PubMed ID: 10837170)
1. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.
Carter JJ; Koutsky LA; Hughes JP; Lee SK; Kuypers J; Kiviat N; Galloway DA
J Infect Dis; 2000 Jun; 181(6):1911-9. PubMed ID: 10837170
[TBL] [Abstract][Full Text] [Related]
2. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women.
Carter JJ; Koutsky LA; Wipf GC; Christensen ND; Lee SK; Kuypers J; Kiviat N; Galloway DA
J Infect Dis; 1996 Nov; 174(5):927-36. PubMed ID: 8896492
[TBL] [Abstract][Full Text] [Related]
3. Type-specific antiviral antibodies to genital human papillomavirus types in mothers and newborns.
Heim K; Hudelist G; Geier A; Szedenik H; Christensen ND; Concin N; Bergant A; Volgger B; Czerwenka K; Höpfl R
Reprod Sci; 2007 Dec; 14(8):806-14. PubMed ID: 18089599
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus antibody responses among patients with incident cervical carcinoma.
Wang Z; Konya J; Avall-Lundkvist E; Sapp M; Dillner J; Dillner L
J Med Virol; 1997 Aug; 52(4):436-40. PubMed ID: 9260694
[TBL] [Abstract][Full Text] [Related]
5. Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions.
Hagensee ME; Koutsky LA; Lee SK; Grubert T; Kuypers J; Kiviat NB; Galloway DA
J Infect Dis; 2000 Apr; 181(4):1234-9. PubMed ID: 10753726
[TBL] [Abstract][Full Text] [Related]
6. Serum immunoglobulin A response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women.
Viscidi RP; Ahdieh-Grant L; Schneider MF; Clayman B; Massad LS; Anastos KM; Burk RD; Minkoff H; Palefsky J; Levine A; Strickler H
J Infect Dis; 2003 Dec; 188(12):1834-44. PubMed ID: 14673762
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women.
Viscidi RP; Snyder B; Cu-Uvin S; Hogan JW; Clayman B; Klein RS; Sobel J; Shah KV
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):283-8. PubMed ID: 15668510
[TBL] [Abstract][Full Text] [Related]
8. Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women.
Viscidi RP; Ahdieh-Grant L; Clayman B; Fox K; Massad LS; Cu-Uvin S; Shah KV; Anastos KM; Squires KE; Duerr A; Jamieson DJ; Burk RD; Klein RS; Minkoff H; Palefsky J; Strickler H; Schuman P; Piessens E; Miotti P
J Infect Dis; 2003 Jan; 187(2):194-205. PubMed ID: 12552444
[TBL] [Abstract][Full Text] [Related]
9. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand.
Sukvirach S; Smith JS; Tunsakul S; Muñoz N; Kesararat V; Opasatian O; Chichareon S; Kaenploy V; Ashley R; Meijer CJ; Snijders PJ; Coursaget P; Franceschi S; Herrero R
J Infect Dis; 2003 Apr; 187(8):1246-56. PubMed ID: 12696004
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles.
Ho GY; Studentsov Y; Hall CB; Bierman R; Beardsley L; Lempa M; Burk RD
J Infect Dis; 2002 Sep; 186(6):737-42. PubMed ID: 12198606
[TBL] [Abstract][Full Text] [Related]
11. Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection.
Simen-Kapeu A; Kataja V; Yliskoski M; Syrjänen K; Dillner J; Koskela P; Paavonen J; Lehtinen M
Scand J Infect Dis; 2008; 40(9):745-51. PubMed ID: 19086247
[TBL] [Abstract][Full Text] [Related]
12. Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women.
Petter A; Heim K; Guger M; Ciresa-Kö Nig A; Christensen N; Sarcletti M; Wieland U; Pfister H; Zangerle R; Höpfl R
J Gen Virol; 2000 Mar; 81(Pt 3):701-8. PubMed ID: 10675407
[TBL] [Abstract][Full Text] [Related]
13. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
Roden RB; Yutzy WH; Fallon R; Inglis S; Lowy DR; Schiller JT
Virology; 2000 May; 270(2):254-7. PubMed ID: 10792983
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus vaccine development.
Fife KH
Australas J Dermatol; 1998 Nov; 39 Suppl 1():S8-10. PubMed ID: 9842094
[TBL] [Abstract][Full Text] [Related]
15. The seroprevalence of IgG antibodies to human papillomavirus (HPV) types HPV-16, HPV-18, and HPV-11 capsid-antigens in mothers and their children.
Marais DJ; Sampson CC; Urban MI; Sitas F; Wiliamson AL
J Med Virol; 2007 Sep; 79(9):1370-4. PubMed ID: 17607783
[TBL] [Abstract][Full Text] [Related]
16. Detection of HPV types and neutralizing antibodies in Gansu province, China.
Wu X; Zhang C; Feng S; Liu C; Li Y; Yang Y; Gao J; Li H; Meng S; Li L; Zhang Y; Hu X; Wu X; Lin L; Li X; Wang Y
J Med Virol; 2009 Apr; 81(4):693-702. PubMed ID: 19235880
[TBL] [Abstract][Full Text] [Related]
17. Factors predicting the persistence of genital human papillomavirus infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up.
Branca M; Garbuglia AR; Benedetto A; Cappiello T; Leoncini L; Migliore G; Agarossi A; Syrjänen K;
Int J STD AIDS; 2003 Jun; 14(6):417-25. PubMed ID: 12816671
[TBL] [Abstract][Full Text] [Related]
18. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.
Kirnbauer R; Hubbert NL; Wheeler CM; Becker TM; Lowy DR; Schiller JT
J Natl Cancer Inst; 1994 Apr; 86(7):494-9. PubMed ID: 8133532
[TBL] [Abstract][Full Text] [Related]
19. Concurrent and sequential acquisition of different genital human papillomavirus types.
Thomas KK; Hughes JP; Kuypers JM; Kiviat NB; Lee SK; Adam DE; Koutsky LA
J Infect Dis; 2000 Oct; 182(4):1097-102. PubMed ID: 10979905
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus type specific DNA and RNA persistence--implications for cervical disease progression and monitoring.
Cuschieri KS; Whitley MJ; Cubie HA
J Med Virol; 2004 May; 73(1):65-70. PubMed ID: 15042650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
